United States - English - NLM (National Library of Medicine)

piramal critical care inc. - cefepime hydrochloride (unii: i8x1o0607p) (cefepime - unii:807pw4vqe3) - 1.1 pneumonia cefepime for injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae, including cases associated with concurrent bacteremia, pseudomonas aeruginosa, klebsiella pneumoniae, or enterobacter species. 1.2 empiric therapy for febrile neutropenic patients cefepime for injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see clinical studie s ( 14.1)]. 1.3 uncomplicated and complicated urinary tract infections (including pyelonephritis) cefepime for injection is indicated in the treatment of uncomplicated and co

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

hankook korus pharm co. - cefepime (cefepime hydrochloride) - powder for solution for injection - 1000mg

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefepime hydrochloride - injection - each vial contains cefepime hydrochloride equivalent to cefepime 500,0 mg

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefepime hydrochloride - injection - each vial contains cefepime hydrochloride equivalent to cefepime 1000,0 mg

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefepime hydrochloride - injection - each vial contains cefepime hydrochloride equivalent to cefepime 2000,0 mg

United States - English - NLM (National Library of Medicine)

apotex corp. - cefepime hydrochloride (unii: i8x1o0607p) (cefepime - unii:807pw4vqe3) - cefepime for injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae , including cases associated with concurrent bacteremia, pseudomonas aeruginosa , klebsiella pneumoniae , or enterobacter species. cefepime for injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see clinical studies (14.1) ]. cefepime for injection is indicated in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by susceptible isolates of escherichia coli or klebsiella pneumoniae , when the infec

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - cefepime -

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - cefepime -

United States - English - NLM (National Library of Medicine)

xellia pharmaceuticals usa llc - cefepime hydrochloride (unii: i8x1o0607p) (cefepime - unii:807pw4vqe3) - cefepime for injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae , including cases associated with concurrent bacteremia, pseudomonas aeruginosa , klebsiella pneumoniae , or enterobacter species. cefepime for injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see clinical studies (14.1)] . cefepime for injection is indicated in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by susceptible isolates of escherichia coli or klebsiella pneumoniae , when the infec

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - cefepime dihydrochloride monohydrate 1.1518 g equivalent to 1 g cefepime free base; cefepime dihydrochloride monohydrate 1.189 g equivalent to 1 g cefepime free base - powder for injection - 1 g - active: cefepime dihydrochloride monohydrate 1.1518 g equivalent to 1 g cefepime free base excipient: arginine active: cefepime dihydrochloride monohydrate 1.189 g equivalent to 1 g cefepime free base excipient: arginine - cefepime mylan is indicated in adults for the treatment of the infections listed below when caused by susceptible bacteria. · lower respiratory tract infections, including pneumonia and bronchitis. · urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. · skin and skin structure infections. · septicaemia. · intra-abdominal infections, including peritonitis and biliary tract infections. · empiric treatment of febrile neutropenia.